ARAnne Des Roches

Anne Des Roches

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Des Roches has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Louis Paradis

    Département D'immunologie et Allergie Pédiatrique CHU Sainte‐Justine Montréal Québec Canada

    18 shared publications
  • François Graham

    Division of Clinical Immunology and Allergy, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Qc, Canada

    9 shared publications
  • Jean Paradis

    Allergy and Clinical Immunology, Centre Hospitalier de l’Universite de Montreal (CHUM), Montreal, Canada

    9 shared publications
  • Philippe Bégin

    Division of Clinical Immunology and Allergy, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Qc, Canada

    8 shared publications
  • Kathryn Samaan

    Département D'immunologie et Allergie Pédiatrique CHU Sainte‐Justine Montréal Québec Canada

    6 shared publications
  • Philippe Bégin

    Département D'immunologie et Allergie Pédiatrique CHU Sainte‐Justine Montréal Québec Canada

    6 shared publications

Latest Publications

  • Open Access

    Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

    by Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, et al.

    Background: Unmet needs remain for disease‐modifying interventions for the treatment of severe persistent food allergies. In mice models, abatacept, a cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) immunoglobulin fusion protein, promotes immune tolerance to food proteins, and suppresses the initial allergen‐related induction of specific immunoglobulin E (IgE) when used as an adjuvant to allergen immunotherapy. Methods: In this Phase 2a placebo‐controlled clinical trial, 14 peanut‐allergic participants (14–50 years old) with specific IgE > 50 kU/L were randomized 1:1 to adjuvant abatacept vs. placebo to peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. With the hypothesis that abatacept suppresses the transient OIT‐induced increase in specific IgE, the primary outcome was the relative change from baseline of the peanut‐specific/total IgE ratio at 24 weeks. Sustained unresponsiveness was assessed as a secondary outcome with repeated oral food challenges (OFCs) following incremental periods of peanut avoidance. Results: No significant difference in the relative change in peanut‐specific/total IgE ratio from baseline was observed between groups (placebo group 87.9% vs. abatacept group 48.2%, p ‐value 0.26). Median minimal reactive doses on repeated OFCs were similar in both groups (3000 mg) after 4 weeks of peanut avoidance. Lower adverse event rates including anaphylaxis were observed in the abatacept group (5.9 vs. 10 per participant, p ‐value 0.006). Conclusion: Compared to placebo, abatacept did not suppress the allergen‐related induction of peanut‐specific IgE relative to their total at 24 weeks, but improved OIT tolerability in this severely allergic adult population. Independently of abatacept, most participants achieved sustained unresponsiveness with OIT.

  • Open Access

    Oral immunotherapy for the treatment of pumpkin seed allergy: a real-world case series

    by Victor Paradis, Meghan Kanou, Louis Paradis, Roxane Labrosse, Kathryn Samaan, Philippe Bégin, Florence Gingras-Lessard, François Graham, Anne Des Roches

    Background: Pumpkin seed, a member of the Cucurbitaceae family, is increasingly consumed because of its high protein content and perceived health benefits. Along with its growing use, cases of pumpkin seed allergy are being reported. However, data on pumpkin seed allergy and oral immunotherapy (OIT) remain scarce. Methods: We conducted a retrospective chart review at a tertiary pediatric center (Sainte-Justine University Hospital Center, Montreal, Canada) including all patients who initiated or completed pumpkin seed OIT since 2019. OIT protocols were individualized, with dose increases typically performed every four weeks. Target maintenance doses were at least 300 mg of pumpkin seed protein. Results: Eleven patients (median age at OIT initiation: 6.5 years; range 1–12) underwent pumpkin seed OIT. Ten patients (91%) reached maintenance dosing within a median of 9.5 months (range 6–22) while one patient discontinued OIT due to persistent abdominal pain. No anaphylactic reactions occurred at home during treatment. Two anaphylactic reactions requiring epinephrine occurred during in-clinic up-dosing visits in a single patient, despite this, the patient ultimately achieved maintenance. Gastrointestinal and oral symptoms were the most frequent adverse events and were generally managed with temporary premedication. Most patients (91%) underwent concomitant multi-food OIT. Patients with significant adverse reactions had high ratios of pumpkin-specific IgE to total IgE. Conclusion: Pumpkin seed OIT appears feasible in a highly atopic pediatric population, with a safety profile comparable to that reported for OIT to other food allergens. Given the increasing dietary exposure to pumpkin seeds, larger prospective studies are needed to better define risk factors and long-term outcomes.


  • Single-dose yellow fever vaccination is well tolerated in egg-allergic children despite positive intradermal test to the vaccine

    by Marc-Antoine Bédard, François Graham, Louis Paradis, Kathryn Samaan, Philippe Bégin, Anne Des Roches


  • Evaluation of Adverse Reactions to Vaccines

    by Anne Des Roches, François Graham, Philippe Begin, Louis Paradis, Michael Gold


  • Open Access

    Immunoglobulin E-Binding Pattern of Canadian Peanut Allergic Children and Cross-Reactivity with Almond, Hazelnut and Pistachio

    by Mélanie Pitre, Lamia L’hocine, Allaoua Achouri, Martin Blaquière, Anne Des Roches

    Peanut allergic individuals can be both co-sensitized and co-allergic to peanut and tree nuts. At the moment, standard diagnostic approaches do not always allow differentiation between clinically relevant sensitization and nonsignificant cross-reactions, and the responsibility of each allergen remains unclear. The objective of this study was therefore to determine a peanut sensitization profile in a cohort of Canadian peanut allergic children and assess the immunoglobulin E (IgE) molecular cross-reactivity between peanut, almond, hazelnut and pistachio. The specific IgE (sIgE) levels of each patient serum were determined by ImmunoCAP, indirect ELISA and immunoblot to examine their sIgE-binding levels and profiles to peanut proteins. Reciprocal inhibition ELISA and immunoblotting were used to study sIgE cross-reactions between peanut and the selected tree nuts using an adjusted and representative serum pool of the nine allergic patients. The results showed that the prepared peanut and tree nut protein extracts allowed for the detection of the majority of peanut and selected tree nut known allergens. The reciprocal inhibition ELISA experiments showed limited sIgE cross-reactivities between peanut and the studied tree nuts, with peanut being most likely the sensitizing allergen and tree nuts the cross-reactive ones. In the case of hazelnut and pistachio, a coexisting primary sensitization to hazelnut and pistachio was also demonstrated in the serum pool. Reciprocal inhibition immunoblotting further revealed that storage proteins (2S albumin, 7S vicilin and 11S legumin) could possibly account for the observed IgE-cross-reactions between peanut and the studied tree nuts in this cohort of allergic individuals. It also demonstrated the importance of conformational epitopes in the exhibited cross-reactions.


  • Open Access

    Sensitivity and specificity of double-blinded penicillin skin testing in relation to oral provocation with amoxicillin in children

    by Roxane Labrosse, Louis Paradis, Kathryn Samaan, Jonathan Lacombe-Barrios, Jean Paradis, Philippe Bégin, Anne Des Roches

    Current recommendations for the management of penicillin allergy are to perform penicillin skin testing (PST) with penicilloyl-polylysine (PPL) and benzylpenicillin (BP) prior to drug challenge with amoxicillin. However, the role of PST is increasingly questioned in the pediatric setting. To resolve the question of PST’s diagnostic accuracy, consecutive children with a history of non-life-threatening penicillin allergy referred to a tertiary-care allergy center were recruited to undergo double-blinded PST with PPL and BP prior to drug provocation to amoxicillin. Five of 158 participants (3.2%) presented with an immediate or accelerated reaction upon amoxicillin challenge, none of which were severe. Only one of these had positive PST (20%), compared to 15 of 153 amoxicillin tolerant participants (9.8%). The sensitivity and specificity of PST with PPL and BP for reacting upon amoxicillin challenge were 20% (95% CI: 0.5–71.6%) and 90% (95% CI: 84.4–94.4%), respectively. These results argue against the routine use of PST as a preliminary step to drug provocation with amoxicillin in this population, as it is unlikely to significantly alter pre-test probability of reacting to challenge.


  • Open Access

    Anaphylaxis to clindamycin following cutaneous exposure

    by N. Paradis, L. Marois, L. Paradis, F. Graham, P. Bégin, A. Des Roches

    Background: The role and importance of skin barrier as an immunologic organ and as a potent way of sensitization is well known. However, antibiotics anaphylaxis following skin sensitization has not been reported. Case presentation: We describe the first case of intravenous clindamycin anaphylaxis, with likely sensitization due to previous topical exposure to clindamycin gel for acne in a 14-year-old boy with history of atopy and mild atopic dermatitis. Conclusion: This case highlights the potential sensitization to drug allergens, including antibiotics, via the skin.


  • Efficacy and Safety of 5-Day Challenge for the Evaluation of Nonsevere Amoxicillin Allergy in Children

    by Roxane Labrosse, Louis Paradis, Jonathan Lacombe-Barrios, Kathryn Samaan, François Graham, Jean Paradis, Philipps Bégin, Anne Des Roches


  • Open Access

    Comparison of ImmunoCAP and Immulite serum specific IgE assays for the assessment of egg allergy

    by François Graham, Philippe Bégin, Louis Paradis, Jonathan Lacombe-Barrios, Jean Paradis, Anne Des Roches

    Egg specific IgE levels are frequently used in combination with skin-prick tests to guide clinical decisions and to monitor egg allergy evolution in children. We compared both Immulite and ImmunoCAP egg specific IgE assays in egg allergic children, and found a linear correlation between both assays with a mean Immulite:ImmunoCAP ratio of 3. This is relevant information for clinicans wishing to estimate values from one assay to the other, as most literature has been published using the ImmunoCAP system.